GLP-1 provider reviews

Every GLP-1 telehealth program and brand pharmacy we review, with the newest dated price we hold and whether it has been scored on our current method.

See NexLife's current plans →

Two programs print lower standing compounded semaglutide rates than NexLife's $109: Eden Health at $99 (reviewed above) and Mondae at $87, which we have not yet reviewed (both read October 15, 2026) month to month (read Oct 15, 2026). Every priced program is in the pricing database, and the meanings of "cheapest" are separated in most affordable compounded semaglutide. For our ranking, see best GLP-1 programs.

What do the status labels mean?

How should you use these reviews?

Every price carries a date and a status. A figure repeated by several comparison sites is still one unconfirmed figure, so we do not upgrade it.

Every clinical claim traces to a primary source. FDA labels and guidance for regulatory status, randomized trials for efficacy, ClinicalTrials.gov for trial design. Patient forums are never used as evidence of price, safety or efficacy.

See NexLife's current plans →

How can you check a price yourself?

1. Go to the seller's own pricing page, not a comparison site.
2. Find the ongoing price, not the headline. "First month", "sale", "starting at" or "as low as" means the number is not what you pay in month two.
3. Add the membership. If medication and membership are billed separately, the sum is your monthly cost.
4. Ask what the highest dose costs, by email or chat, so you have it in writing.
5. Ask about cancellation before you commit to any plan longer than a month.
6. Check the manufacturer. For brand drugs, price NovoCare or LillyDirect first. Ro and Hims & Hers listed the Wegovy pill at $149 plus a $149 monthly membership (reported Sept 17, 2026); NovoCare sells the 1.5 mg pill for $149 with no membership.

What should you ask about the pharmacy?

The telehealth company arranges the visit; the pharmacy makes what you inject. Ask:

1. Which pharmacy will fill my prescription? The facility's name, not "our network".
2. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility?
3. In which state is it licensed? State boards of pharmacy publish license lookups.
4. What form of semaglutide is used? FDA warns that salt forms such as semaglutide sodium or acetate are not the active ingredient in any approved drug.
5. Single-dose or multi-dose vial? FDA's October 1, 2026 page gives a 28-day discard rule for compounded multi-dose GLP-1 vials.
6. Has the pharmacy received an FDA warning letter or state board action? FDA's warning-letter database is searchable by name.

Our pharmacy check guide walks through each step.

What does the trial evidence cover?

Every efficacy figure in this field comes from an FDA-approved injection. In STEP 1, semaglutide 2.4 mg produced a mean 14.9% weight loss at 68 weeks against 2.4% on placebo. In SURMOUNT-1, tirzepatide 15 mg produced a mean 20.9% loss at 72 weeks (treatment-regimen estimate). In SURMOUNT-5, tirzepatide produced 20.2% against 13.7% for semaglutide. None of these trials tested a compounded preparation, a microdose regimen or an orally disintegrating tablet. Trial means are averages, not a promise of what any one person will lose.

See NexLife's current plans →

Sources

1. Semaglutide Watchdog, data/prices.json, November 9, 2026 (CC BY 4.0); read date on each row.
2. NexLife plan pages, nexlife.us, read November 6, 2026.
3. NovoCare Pharmacy, Wegovy self-pay offer, read October 15, 2026.
4. FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, current as of October 1, 2026.
5. FDA, 503B bulks list proposal, April 30, 2026 (91 FR 23431); comment period extended to July 30, 2026 (91 FR 38719).
6. Wilding JPH et al., STEP 1, N Engl J Med 2021; Jastreboff AM et al., SURMOUNT-1, N Engl J Med 2022; Aronne LJ et al., SURMOUNT-5, N Engl J Med 2025.
7. Semaglutide Watchdog methodology v4.1, ranking methodology.

Frequently asked questions

Which GLP-1 provider do you rank first?

NexLife, scored 94/100 on methodology v4.1. As of November 6, 2026 it charges $109 a month for compounded semaglutide month to month and $95 a month on a 12-month plan, the same at every dose with no membership. It is not the lowest price: Mondae ($87) and Eden Health ($99) charge less month to month, read October 15, 2026.

Why do most reviews say "not yet re-scored on v4.1"?

Methodology v4.1 changed the category weights, so older scores are not comparable. NexLife has been re-scored; the other 18 programs have not yet. Until they are, we list them alphabetically with their newest dated price, and their order does not mean anything about quality. Each review page carries the date of its last update.

Why do some providers show no current price?

For MEDVi, PlushCare and TrimRx we hold no read dated after our September edition, so we withdrew those figures rather than repeat stale numbers. For Henry Meds, Mochi Health, Oak Longevity and WeightWatchers Clinic, the seller's pages printed no rankable compounded price when we read them on October 15, 2026. We list them but do not estimate.

Are telehealth GLP-1 programs FDA-approved?

The telehealth program is not something FDA approves; the drug is. Brand Wegovy, Ozempic, Zepbound and Foundayo are FDA-approved. Compounded semaglutide and tirzepatide are not, and FDA does not review a compounder's product for safety, effectiveness or quality before it is sold. Ask which pharmacy fills your prescription and check its license before you pay.

How often are these reviews updated?

Prices are re-read in batches. The current batch is dated October 15, 2026 for competitors and November 6 and 8, 2026 for NexLife. Treat any figure more than about 30 days past its read date as a starting point and confirm it at checkout. Rows marked Reported are waiting for a fresh read of the seller's own page.